Laurus Labs Ltd. (LAURUSLABS) Share Price Falls 3.18% Today; What The Move Means

Laurus Labs fell to Rs 1782.5, down 3.18% today, taking its market capitalisation to Rs 99,474.18 crore and placing the stock on a large-cap price fall screen.

Laurus Labs Share Price was under pressure on 14 August 2026, with the stock trading at Rs 1782.5, down 3.18% from the previous close of Rs 1841.05. The move reduced the company’s market capitalisation to Rs 99,474.18 crore and put the stock on a verified large-cap price fall screen tracked by Univest. For investors searching Laurus Labs Share Price Today or Laurus Labs Stock News, the immediate takeaway is straightforward: this was a notable same-day decline with clear weakness from the opening levels through the session low.

The stock opened at Rs 1853.5, which was also the day’s high, and then slipped to an intraday low of Rs 1777.25 before stabilising slightly. That sequence matters because it shows selling pressure emerged early and the stock never reclaimed its opening range. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the decline. In other words, Laurus Labs Share Price is trending because of the size and structure of the move, not because the input data identifies a confirmed trigger.

For Share Market Today participants, this kind of price action becomes relevant when it combines a meaningful percentage decline with sizeable market capitalisation. Univest is therefore looking at the move through four lenses: what happened in today’s session, what the volume and turnover suggest, how the company sits within the Healthcare sector benchmark, and how its scale compares with the listed peers supplied in the dataset.

Laurus Labs Ltd. (LAURUSLABS) Share Price Today: Price Action Analysis

Laurus Labs Ltd. (LAURUSLABS) traded at Rs 1,782.5. versus the previous close of Rs 1,841.05, a fall of 3.18%. The stock opened at Rs 1,853.5, reached Rs 1,853.5, touched Rs 1,777.25. Reported volume was 47,014.

Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis

Laurus Labs Fundamental Analysis in this dataset is centred less on detailed company financial ratios and more on size, market standing and comparative context. With a market capitalisation of Rs 99,474.18 crore, Laurus Labs is firmly in the large-cap bracket within the workflow classification. That does not by itself say whether the business is expensive, inexpensive, high quality or low quality, but it does indicate the stock’s movement matters more widely in the Indian Stock Market because larger companies often attract greater institutional and benchmark attention.

The present price of Rs 1782.5 against a previous close of Rs 1841.05 highlights the day’s equity market reaction, while the turnover figure of Rs 8.38 crore and total volume of 15,98,897 shares show that this was not an isolated or illiquid print. For investors following Laurus Labs Stock News and Laurus Labs Share News, this is a reminder that large-cap price swings can become market-relevant even when the supplied data does not identify a company-specific reason.

Because the dataset does not provide company-level P/E Ratio, P/B Ratio, ROE, ROCE, EPS, Book Value, Dividend Yield, debt metrics or cash-flow figures for Laurus Labs itself, the most reliable fundamental context comes from where the company sits in relation to the Healthcare benchmark universe and the peer basket supplied later in this report. That matters because market capitalisation alone tells investors about size, not earnings power, balance-sheet quality or valuation comfort.

From a pure stock analysis perspective, Laurus Labs Share Price is drawing attention today because a 3.18% fall in a company valued at nearly Rs 1 lakh crore has more significance than the same percentage move in a much smaller name. Univest therefore treats the present move as a meaningful market update, but not as a standalone verdict on business quality. The more useful next step is to read the decline against sector and peer metrics rather than against price alone.

Sector and Industry Context

Laurus Labs Ltd. (LAURUSLABS) is classified under sector: Healthcare.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

The Healthcare benchmark snapshot shows a broad valuation and profitability range across a large universe, which helps place Laurus Labs Share Price in perspective. The sector dataset covers 196 companies, making it a meaningful comparison set for understanding how investors are pricing Healthcare businesses across market-cap bands.

The supplied Healthcare benchmark is wide and diverse. Across the same sector universe of 196 companies, the median P/E stands at 26.2 while the average P/E is 75.33. The range is especially broad, with the minimum at 3.29 and the maximum at 3299.57, showing how dispersed earnings valuations are in the space. On P/B, the median is 1.96 and the average is 2.65, with a minimum of -10.01 and a maximum of 16.63. That spread suggests the sector includes everything from stressed balance-sheet situations to richly valued specialist businesses.

Profitability indicators also vary meaningfully across the Healthcare pack. The median ROE is 11.07 and the average ROE is 15.46 based on 195 companies. The median ROCE is 13.35 and the average ROCE is 17.73, again across 195 companies. For market capitalisation, the median is Rs 141.55 crore and the average is Rs 465.17 crore. The smallest company in the benchmark is at Rs 3.67 crore while the largest is at Rs 2995.34 crore within the displayed sector sample.

This comparison is useful because Laurus Labs, at Rs 99,474.18 crore in market capitalisation, stands far above the benchmark median and average market-cap levels shown in the sector snapshot. That does not indicate valuation by itself, but it clearly positions the company as a scale outlier relative to the broader Healthcare set used here. Laurus Labs Share Price Today is therefore moving in a company that is substantially larger than the typical benchmark constituent captured in the supplied same-sector dataset.

For readers of Laurus Labs Latest News and general Market News, the implication is simple: today’s decline should be read not just as price action but as movement in a heavyweight Healthcare name. Univest sees the benchmark data as evidence that sector-level dispersion is high, which makes direct peer comparison the more precise next step.

Peer Comparison

Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 99,474.18 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

The supplied peer group shows companies mainly from Pharmaceuticals & Drugs, with one Hospital & Healthcare Services name, and it offers a practical way to compare market size, valuation bands and profitability metrics. Laurus Labs is much larger in market capitalisation than every displayed peer, so today’s share price fall is occurring in a very different scale category.

The highest market capitalisation in the peer list is Dishman Carbogen Amcis Ltd. at Rs 2995.34 crore, followed by Beta Drugs Ltd. at Rs 2836.87 crore and Dr Agarwals Eye Hospital Ltd. at Rs 2644.55 crore. Other peers include Hikal Ltd. at Rs 2619.52 crore, Ind-Swift Laboratories Ltd. at Rs 2605.37 crore, Panacea Biotec Ltd. at Rs 2450.34 crore, Sai Parenteral’s Ltd. at Rs 2441.79 crore, Solara Active Pharma Sciences Ltd. at Rs 2436.78 crore, Fredun Pharmaceuticals Ltd. at Rs 2304.91 crore and Venus Remedies Ltd. at Rs 2214.91 crore. Against that backdrop, Laurus Labs Share Price is attached to a company whose market capitalisation is vastly above the supplied peer band.

On valuation, the peers with reported P/E ratios span from 19.99 for Venus Remedies to 174.73 for Sai Parenteral’s. Dishman Carbogen is at 31.94, Dr Agarwals Eye Hospital at 34.7, Ind-Swift Laboratories at 45.02, Fredun Pharmaceuticals at 56.53 and Beta Drugs at 69.35. The peer P/B multiples also vary sharply, from 0.47 for Dishman Carbogen to 10.97 for Beta Drugs. Hikal is at 2.24, Panacea Biotec at 3.04, Solara at 1.96, Fredun at 8.44 and Venus Remedies at 3.38.

Profitability divergence is equally visible. Beta Drugs shows ROE of 18.65 and ROCE of 22.17, while Solara reports ROE of 17.23 and ROCE of 15.34. Hikal posts ROE of 15.22 and ROCE of 16.15. At the weaker end, Dishman Carbogen has ROE of -2.89 and ROCE of -0.26, Dr Agarwals Eye Hospital has ROE of -2.6 and ROCE of 16.92, and Ind-Swift Laboratories has ROE of -0.78 with ROCE of 8.31. This variation shows why Laurus Labs Stock Analysis cannot rest on price movement alone. In the absence of company-specific profitability ratios in the dataset, the most defensible conclusion is that Laurus Labs is trading as a much larger Healthcare name than the displayed peers, and that today’s fall deserves monitoring in a context where sector valuations and returns can differ materially from one business model to another.

Why Investors Are Watching Laurus Labs

Laurus Labs Share Price is being watched because the stock recorded a screen-qualifying decline in the Large Cap category and did so with a clear intraday weakening pattern. The session matters not only because of the 3.18% fall, but because the company’s Rs 99,474.18 crore market capitalisation gives the move broader visibility in Stocks in News and Top Losers Today screens.

• Verified price action: the stock declined Rs 58.55 to Rs 1782.5 from a previous close of Rs 1841.05.
• Session structure: the day open and day high were both Rs 1853.5, while the day low was Rs 1777.25, pointing to sustained selling pressure.
• Volume footprint: total volume reached 15,98,897 shares, with 15,51,883 on NSE and 47,014 on BSE.
• Scale effect: market capitalisation of Rs 99,474.18 crore makes this a large-cap price fall rather than a small-name fluctuation.
• Sector position: the Healthcare benchmark covers 196 companies, but the company’s size stands far above the benchmark median and average market caps shown.

What should investors monitor next? The most practical areas are whether Laurus Labs Share Price can move away from the day low, whether turnover remains elevated in the next sessions, and whether the stock continues to feature among stocks under pressure. Univest would also keep the sector benchmark and peer valuation range in view when reading subsequent Laurus Labs Share Price Update headlines.

About Laurus Labs

Laurus Labs Ltd. is represented in this dataset as a listed Healthcare company tracked on the Indian stock market under the symbol LAURUSLABS. The article inputs place the stock in a large-cap bucket based on market capitalisation, with the company valued at Rs 99,474.18 crore at the captured market price. That alone makes Laurus Labs relevant for investors monitoring broader Healthcare exposure across NSE and BSE.

The surrounding comparison set indicates that the market is evaluating Laurus Labs within a Healthcare ecosystem that includes Pharmaceuticals & Drugs companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral’s, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies, along with Dr Agarwals Eye Hospital in Hospital & Healthcare Services. Even without a detailed company description in the supplied data, this helps frame Laurus Labs as part of a sector where valuations, book multiples and profitability metrics can vary sharply from one listed business to another.

For readers searching Laurus Labs Company News, Laurus Labs Earnings or Laurus Labs Financial Results, the key point in today’s article is not to extend beyond verified inputs. Univest therefore focuses on what the dataset firmly establishes: Laurus Labs is a high-market-cap Healthcare stock, today it recorded a notable share price decline, and that decline is significant enough to merit close market and sector tracking.

Track Laurus Labs Share Price on Univest

Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

If you are following Laurus Labs Share Price, Univest offers a practical way to track the stock beyond one trading session. Users can monitor Laurus Labs Share Price Today, daily price action, 52-week levels, market capitalisation trends, sector context and peer positioning in one place. The platform also helps investors organise stock updates alongside broader Stock Market Today screens, including top decliners and market movers.

For those comparing Healthcare names, Univest can be used to follow live share price behaviour, valuation ratios when available, shareholding pattern updates when disclosed, and changes in relative sector positioning over time. That makes Laurus Labs Share Price easier to assess as part of a continuing market update rather than as an isolated one-day move.

Frequently Asked Questions

Why is Laurus Labs Share Price falling today?

Ans. Laurus Labs Share Price is down 3.18% today to Rs 1782.5 from the previous close of Rs 1841.05. The supplied data confirms the decline and the intraday weakness, but it does not establish a company-specific catalyst.

What is Laurus Labs Share Price Today?

Ans. Laurus Labs Share Price Today is Rs 1782.5 at the captured timestamp of 14 August 2026 at 3:17:28 PM IST. The stock was down Rs 58.55 on the day, equivalent to a 3.18% decline.

How did Laurus Labs perform intraday?

Ans. The stock opened at Rs 1853.5, which was also the day’s high, and later fell to a low of Rs 1777.25. Trading near the lower end of that range indicates sellers controlled most of the session.

Is Laurus Labs among the top losers today?

Ans. Yes. The stock appears under the supplied TOP_LOSERS screener and the event is marked as PRICE_FALL_THRESHOLD. That means the decline was large enough to qualify for a dedicated price fall screen in today’s market update.

What is the market capitalisation of Laurus Labs?

Ans. Laurus Labs has a market capitalisation of Rs 99,474.18 crore in the supplied dataset. That places it in the Large Cap category for this workflow, making today’s 3.18% fall more visible than a similar move in smaller stocks.

How much volume was traded in Laurus Labs today?

Ans. Total traded volume in Laurus Labs stood at 15,98,897 shares. Of this, 15,51,883 shares were on NSE and 47,014 shares were on BSE, showing that the stock saw active participation during the decline.

What was the turnover in Laurus Labs today?

Ans. The supplied turnover figure is Rs 8.38 crore. Along with total volume of 15,98,897 shares and a 3.18% price fall, that indicates the move was backed by visible trading activity rather than an isolated print.

How does Laurus Labs compare with the Healthcare sector benchmark?

Ans. The Healthcare benchmark covers 196 companies, with median market capitalisation of Rs 141.55 crore and average market capitalisation of Rs 465.17 crore. Laurus Labs, at Rs 99,474.18 crore, is far larger than those benchmark levels.

Which peers are included in this Laurus Labs comparison?

Ans. The supplied peer set includes Dishman Carbogen Amcis, Beta Drugs, Dr Agarwals Eye Hospital, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral's, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies across Healthcare segments.

What should investors monitor after this Laurus Labs Share Price fall?

Ans. Investors can monitor whether the stock moves away from the day low of Rs 1777.25, whether trading activity remains elevated after today’s 15,98,897-share volume, and whether Laurus Labs continues to feature among top decliners or stocks under pressure.